Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat
Authors
Keywords
Transglutaminase-2, Vorinostat, Histone deacetylase inhibitors, Cancer
Journal
AMINO ACIDS
Volume 49, Issue 3, Pages 517-528
Publisher
Springer Nature
Online
2016-10-19
DOI
10.1007/s00726-016-2338-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer
- (2016) Marco Napoli et al. CANCER CELL
- A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity
- (2016) K J Falkenberg et al. CELL DEATH AND DIFFERENTIATION
- Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death
- (2016) H Tatsukawa et al. Cell Death & Disease
- Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
- (2016) Qun Wang et al. Oncotarget
- SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells
- (2015) Ling Ding et al. CANCER LETTERS
- FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
- (2015) H.-Z. Lee et al. CLINICAL CANCER RESEARCH
- Panobinostat Approved for Multiple Myeloma
- (2015) Cancer Discovery
- MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor
- (2013) A. R. Chakraborty et al. BLOOD
- Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors
- (2013) Caterina Ieranò et al. CELL CYCLE
- Romidepsin for peripheral T-cell lymphoma
- (2013) Amit Khot et al. Expert Review of Hematology
- Tissue transglutaminase: a new target to reverse cancer drug resistance
- (2011) Alfredo Budillon et al. AMINO ACIDS
- Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance
- (2011) Robert W. Robey et al. MOLECULAR PHARMACEUTICS
- Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors
- (2011) J.-H. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors
- (2010) Hui Song et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
- (2010) E Di Gennaro et al. BRITISH JOURNAL OF CANCER
- Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed
- (2010) Elena Di Gennaro et al. CANCER BIOLOGY & THERAPY
- TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in Colorectal Cancer
- (2009) Norikatsu Miyoshi et al. ANNALS OF SURGICAL ONCOLOGY
- HDACi – Targets beyond chromatin
- (2009) Marc Buchwald et al. CANCER LETTERS
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
- (2009) F. Bruzzese et al. MOLECULAR CANCER THERAPEUTICS
- Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells
- (2009) G -Y Jang et al. ONCOGENE
- In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma
- (2008) G. Di Giacomo et al. AMINO ACIDS
- Protein–polyamine conjugates by transglutaminase 2 as potential markers for antineoplastic screening of natural compounds
- (2008) A. Lentini et al. AMINO ACIDS
- Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling
- (2008) L. Cao et al. CARCINOGENESIS
- Identification of Chemical Inhibitors to Human Tissue Transglutaminase by Screening Existing Drug Libraries
- (2008) Thung-S. Lai et al. CHEMISTRY & BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now